OncoMatch/Clinical Trials/Bladder Cancer (Urothelial)
Bladder Cancer (Urothelial) Clinical Trials
OncoMatch filters Bladder Cancer (Urothelial) trials by the molecular markers that determine eligibility — CD274, FGFR3, ERBB2, MMR, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaBiomarkers tested in Bladder Cancer (Urothelial) trials
These are the molecular markers most commonly required or evaluated in Bladder Cancer (Urothelial) eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.
Top recruiting Bladder Cancer (Urothelial) trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Alliance for Clinical Trials in Oncology
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
National Cancer Institute (NCI)
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Janssen Research & Development, LLC
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
How OncoMatch finds Bladder Cancer (Urothelial) trials for you
AI reads the protocol
Every Bladder Cancer (Urothelial) trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Bladder Cancer (Urothelial) and mark your biomarker results — CD274, FGFR3, ERBB2 — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.